Deciphera Pharmaceuticals’ (DCPH) Hold Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group reaffirmed their hold rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $25.60 price target on the stock, down from their previous price target of $26.00.

Several other research analysts have also recently commented on the company. JPMorgan Chase & Co. boosted their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a neutral rating in a research note on Wednesday, March 20th. Stifel Nicolaus increased their target price on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a buy rating in a research note on Wednesday, February 7th. Finally, Jonestrading reaffirmed a hold rating and issued a $25.60 price target on shares of Deciphera Pharmaceuticals in a report on Monday. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Deciphera Pharmaceuticals presently has an average rating of Moderate Buy and a consensus target price of $23.87.

Deciphera Pharmaceuticals Stock Performance

Deciphera Pharmaceuticals stock opened at $25.28 on Monday. Deciphera Pharmaceuticals has a one year low of $9.90 and a one year high of $25.40. The stock’s 50 day moving average price is $15.78 and its 200 day moving average price is $14.45. The firm has a market capitalization of $2.04 billion, a PE ratio of -11.04 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. The business had revenue of $48.30 million for the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The business’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.60) earnings per share. On average, analysts forecast that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Diversified Trust Co raised its holdings in shares of Deciphera Pharmaceuticals by 6.5% during the first quarter. Diversified Trust Co now owns 12,747 shares of the company’s stock worth $201,000 after purchasing an additional 778 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Deciphera Pharmaceuticals by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Deciphera Pharmaceuticals by 2.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,527 shares of the company’s stock worth $670,000 after acquiring an additional 1,117 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Deciphera Pharmaceuticals by 10.3% in the third quarter. Principal Financial Group Inc. now owns 18,266 shares of the company’s stock valued at $232,000 after acquiring an additional 1,699 shares during the period. Finally, Quest Partners LLC bought a new position in shares of Deciphera Pharmaceuticals during the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 70.96% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.